Ranibizumab for Macular Edema After Branch Retinal Vein Occlusion

Abstract

In IVR treatment for ME after branch retinal vein occlusion, 1+PRN and 3+PRN regimens achieved similar 12-month functional outcomes. Patients with shorter durations to initial PRN injection may require more PRN treatments.

Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections

“…In a previous report by Miwa et al [22] , 23.5% of eyes with BRVO did not require PRN IVR. Considering that blockade of VEGF does not actually ameliorate the occlusion of the affected retinal veins, a high rate of PRN injections may be inevitable and careful monthly observation would be essential.…”

“…Previously, Ito et al [21] reported outcomes following an initial single injection or 3 monthly injections of bevacizumab in a small series of patients with ME after BRVO. Recently, Miwa et al [22] reported that the 1+PRN IVR regimen achieved visual outcomes similar to those achieved by 3+PRN IVR for BRVO. In the current study, the number of anti-VEGF injections in the 1+PRN group (4.1 ± 2.8) were significantly smaller than that in the 3+PRN group (5.9 ± 2.1).…”

Impact of Early Anatomical and Functional Responses to Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion

“…Similarly, in the previous BRVO study of eyes treated with IVB, 21.4% of the eyes with visual gain of more than 5 letters at the last follow-up did not show early visual improvement [27]. In another study comparing the 12-month efficacy of single IVR followed by pro re nata (PRN) with that of three monthly IVR followed by PRN injections for the treatment of macular edema after BRVO, the early VA gain was greater in the eyes with the three monthly injections than those with single injection [19]. This result implies that the early VA responses may vary according to the number of initial loading injection.…”

“…Based on the recent pathogenesis of VEGF, intravitreal anti-VEGF injections are widely used for treating BRVO. Several clinical studies reported that anti-VEGF treatment was beneficial in improving or maintaining visual acuity (VA) [10-19]. Several studies also reported that 57.1–64.9% of all patients showed improvement from the baseline Early Treatment Diabetic Retinopathy Study letter score of ≥15 at 12 months after treatment.…”

A meta‐analysis of patients with treatment‐resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept

“…However, the number of injections required varies widely, with some patients able to maintain control of macular oedema on three monthly injections, whilst others never achieving anatomical success despite monthly intervention (Miwa et al. ). Patients with RVO can show suboptimal response to suppression of VEGF, and in these patients, it is possible that other vasoactive proteins may contribute (Campochiaro et al.…”